Condensed Consolidated Statements of Income (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Revenue
Blood services	$ 1,561,000	$ 1,812,000	$ 5,289,000	$ 5,648,000
Therapeutic services	2,404,000	2,089,000	6,822,000	5,812,000
Total revenue	3,965,000	3,901,000	12,111,000	11,460,000
Operating costs and expenses
Blood services	1,778,000	2,473,000	5,638,000	5,713,000
Therapeutic services	1,635,000	1,511,000	4,640,000	4,251,000
Total operating costs and expenses	3,413,000	3,984,000	10,278,000	9,964,000
Gross profit (loss)	552,000	(83,000)	1,833,000	1,496,000
General and administrative expenses	1,130,000	1,266,000	3,520,000	3,807,000
Loss from operations	(578,000)	(1,349,000)	(1,687,000)	(2,311,000)
Gain on insurance settlement			192,000
Income (loss) from continuing operations before tax	(578,000)	(1,349,000)	(1,495,000)	(2,311,000)
Provision for (benefit of) income taxes		(70,000)	10,000	(60,000)
Loss from continuing operations, net of tax	(578,000)	(1,279,000)	(1,505,000)	(2,251,000)
Income from discontinued operations, net of tax	1,090,000	653,000	1,375,000	1,645,000
Net income (loss)	$ 512,000	$ (626,000)	$ (130,000)	$ (606,000)
Basic
Continuing operations (in Dollars per share)	$ (0.06)	$ (0.13)	$ (0.15)	$ (0.22)
Discontinued operations (in Dollars per share)	$ 0.11	$ 0.06	$ 0.14	$ 0.16
Total (in Dollars per share)	$ 0.05	$ (0.07)	$ (0.01)	$ (0.06)
Diluted
Continuing operations (in Dollars per share)	$ (0.06)	$ (0.13)	$ (0.15)	$ (0.22)
Discontinued operations (in Dollars per share)	$ 0.11	$ 0.06	$ 0.14	$ 0.16
Total (in Dollars per share)	$ 0.05	$ (0.07)	$ (0.01)	$ (0.06)
Weighted average shares outstanding-basic (in Shares)	9,819,982	10,063,610	9,749,018	10,054,149
Weighted average shares outstanding-diluted (in Shares)	9,895,763	10,222,572	9,874,380	10,258,392